Resistance of aspirin during and after pregnancy: A longitudinal cohort study

Weg, Jeske M. bij de; Abheiden, Carolien N H; Fuijkschot, Wessel W.; Harmsze, Ankie M; Boer, Marjon A. de; Thijs, Abel; Vries, J.I.P. de

doi:10.1016/j.preghy.2019.11.008

Cited by 15 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aside from the findings of the ASPRE RCT, the optimal timing and dosage of aspirin prophylaxis were recently reviewed with the observation that there was a dose‐response effect resulting in 150 mg aspirin conferring the most beneficial effect in preventing pre‐eclampsia 14 . This finding is readily explained by several studies demonstrating a 30–40% rate of aspirin resistance in pregnancy that is not evident in the non‐pregnant state 15–17 . The near total initiation of effective aspirin prophylaxis as a result of an individualised risk and a universal ‘one‐stop’ screening approach is important given the previously poor rates.…”

Section: Discussionmentioning

confidence: 99%

“…14 This finding is readily explained by several studies demonstrating a 30-40% rate of aspirin resistance in pregnancy that is not evident in the non-pregnant state. [15][16][17] The near total initiation of effective aspirin prophylaxis as a result of an individualised risk and a universal 'one-stop' screening approach is important given the previously poor rates. This is echoed in the most recent MBRRACE report, where a number of women at increased risk were never offered aspirin prophylaxis.…”

Section: Public Health Implications Of Study Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Implementation of routine first trimester combined screening for pre‐eclampsia: a clinical effectiveness study

Guy

Leslie

Gómez

et al. 2020

BJOG

128

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Public Health Implications Of Study Findingsmentioning

confidence: 99%

Implementation of routine first trimester combined screening for pre‐eclampsia: a clinical effectiveness study

Guy

Leslie

Gómez

et al. 2020

BJOG

128

View full text Add to dashboard Cite

show abstract

“…For comparison, some CT NRRs reported in the contemporary 6,16–29 and original literature 30–53 are shown in Figure 3. In most instances, these NRRs differ from each other and also from the manufacturer ranges, especially for C/ADP.…”

Section: Resultsmentioning

confidence: 99%

“…The Siemens product information CT NRRs are shown by the green horizontal dashed lines. Figure A shows NRRs from some contemporary literature as obtained from the recent literature search (see Methods), and reflecting information from the past 3 years 6,16–29 . Figure B shows NRRs from some early literature as otherwise reviewed in Reference 10 30–53 .…”

Section: Resultsmentioning

confidence: 99%

Harmonizing platelet function analyzer testing and reporting in a large laboratory network

Favaloro

Mohammed

Vong

et al. 2022

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction: The platelet function analyzer (PFA) is a popular platelet function screening instrument, highly sensitive to von Willebrand disease (VWD) and to aspirin therapy, with moderate sensitivity to defects in platelet function and/or deficiencies in platelet number. There are two models, the original PFA-100 and the contemporary PFA-200. Normal reference ranges (NRRs) provided by the manufacturer are the same for both models, instead being based on the type of test cartridge, for which there are two main ones: collagen/epinephrine (C/Epi) and collagen/ adenosine diphosphate (C/ADP). Methods: Comparative evaluations of PFA testing and reporting in six different sites of a large pathology network, aiming to harmonize NRRs and test reporting across all network sites. A separate comparative study of testing a range of samples (n > 150) on a PFA-100 versus that on a PFA-200. Review of contemporary literature. Results: Each site was identified to have a different reporting NRR, which after consolidating data permitted establishment of an agreed harmonized NRR for use across the network (C/Epi: 90-160; C/ADP: 70-124; based on n > 180). Similarly, each site reported and interpreted results in different ways, and after discussion and consolidation, a harmonized approach to interpretation and reporting was achieved. The separate comparative study of PFA-100 versus PFA-200 testing confirmed instrument equivalence. Conclusion:We achieved harmonized NRRs and reporting for PFA testing across a large pathology network. Our approach may be useful for other laboratory networks wishing to harmonize PFA testing.

show abstract

“…Advances in medical technology have led to the discovery of drugs and interventional therapies for atherosclerotic cardiovascular disease ( 1 ). However, available drugs are associated with various adverse effects, including high tolerance ( 2 , 3 ), rhabdomyolysis ( 4 ), and restenosis ( 5 ). It has been shown that natural compounds may confer protection against atherosclerotic cardiovascular disease through various mechanisms ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

With improvement in living standards and average life expectancy, atherosclerotic cardiovascular disease incidences and mortality have been increasing annually. Paeonia suffruticosa, a natural herb, has been used for the treatment of atherosclerotic cardiovascular disease for thousands of years in Eastern countries. Paeonol is an active ingredient extracted from Paeonia suffruticosa. Previous studies have extensively explored the clinical benefits of paeonol. However, comprehensive reviews on the cardiovascular protective effects of paeonol have not been conducted. The current review summarizes studies reporting on the protective effects of paeonol on the cardiovascular system. This study includes studies published in the last 10 years. The biological characteristics of Paeonia suffruticosa, pharmacological mechanisms of paeonol, and its toxicological and pharmacokinetic characteristics were explored. The findings of this study show that paeonol confers protection against atherosclerotic cardiovascular disease through various mechanisms, including inflammation, platelet aggregation, lipid metabolism, mitochondria damage, endoplasmic reticulum stress, autophagy, and non-coding RNA. Further studies should be conducted to elucidate the cardiovascular benefits of paeonol.

show abstract

Resistance of aspirin during and after pregnancy: A longitudinal cohort study

Cited by 15 publications

References 25 publications

Implementation of routine first trimester combined screening for pre‐eclampsia: a clinical effectiveness study

Implementation of routine first trimester combined screening for pre‐eclampsia: a clinical effectiveness study

Harmonizing platelet function analyzer testing and reporting in a large laboratory network

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview

Contact Info

Product

Resources

About